Revance To Present Results From Phase 3 Trial Of DaxibotulinumtoxinA On Cervical Dystonia

Revance Therapeutics Inc. (RVNC) said Thursday that it will present results from its ASPEN-1 Phase 3 clinical trial evaluating the efficacy, duration of effect and safety of DaxibotulinumtoxinA for Injection, for the treatment of cervical dystonia in adults, showing a meaningful reduction in signs and symptoms associated with cervical dystonia.

The company will present an ePoster with a video poster presentation at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress 2021 taking place from September 17-22, 2021.

The company said it looks forward to filing a Supplemental Biologics License Application, which may bring us one step closer to helping patients with this debilitating condition achieve long-lasting symptom relief.

cervical dystonia is a painful and disabling chronic condition in which the neck muscles contract involuntarily, causing abnormal movements and awkward posture of the head and neck.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Tech major Google, owned by Alphabet Inc., has unveiled a new chatbot tool called Bard. The experimental conversational artificial intelligence or AI service is built on a large language model, powered by the company's Language Model for Dialogue Applications or LaMDA. DuPont reported Tuesday a profit from continuing operations for the fourth quarter that decreased 37 percent from last year, hurt by charges related to the intended Rogers transaction. Both adjusted earnings per share from continuing operations and quarterly net sales missed analysts' expectations. The company also provide guidance for the first quarter and the full-year 2023. Shares of Siemens Energy AG were losing around 5 percent in German trading after the energy development company reported Tuesday wider net loss in its first quarter and adjusted fiscal 2023 forecast to now expect net loss same as the prior year. Revenues and orders for the quarter, however, climbed and the company maintained its fiscal 2023 revenue forecast.
Follow RTT